Orchid acquires Karalex to bolster US marketing capability
This article was originally published in Scrip
Executive Summary
Orchid Chemicals and Pharmaceuticals has acquired the US generics marketing and sales services company, Karalex Pharma, for an undisclosed sum. Orchid expects the deal to facilitate "end-to-end" connectivity for its growing US generics business.